Charles River Laboratories (CRL)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- CDMO Preclinicalsrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
LOW DILUTION RISKDilution score: 11/100 (LOW), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 6.05% of float, squeeze risk: LOW
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- Drug Development Inputs & Services Stocks Q2 In Review: Charles River Laboratories (NYSE:CRL) Vs Peers
- Charles River partners with Magellan Stem Cells on cell therapy
- Healthcare Contract Research Organization (CRO) - Global Strategic Business Report: Secure Share of US$63.3 Billion Market by 2032 as IQVIA, ICON, Charles River, and Syneos Health Accelerate AI Trials
- Charles River Collaborates with Magellan Stem Cells to Advance Stem Cell and Regenerative Medicine Development
- Global Synthetic Antibody Library Market Report 2026: Size and Forecast to 2030 | Capitalize on 12% CAGR and AI Design with Charles River, Twist Bioscience, GenScript and AbCellera
- Charles River Laboratories Schedules Third-Quarter 2026 Earnings Release and Conference Call
- Charles River and Autolomous Partner to Transform Laboratory Execution Systems
- Charles River Laboratories (CRL) Stock Fair Value Rises After Analyst Day Target Increases
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for Charles River Laboratories.
Full CRL Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.